pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$PMNProMIS Neurosciences Inc.

$PMN
Toronto, Ontario, CAupdated 5mo ago
SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 1: 1
1Phase 1
Phase 1
PMN-310
Alzheimer's Disease

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view ProMIS Neurosciences Inc. jobs →

News

  • STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment
    Did the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?
    stat · 3h ago
  • STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial
    Sellas' experimental blood cancer immunotherapy reduced the risk of death in clinical trial.
    stat · 2d ago
  • STAT+: What to know about Biogen’s big lupus study readout
    Biogen is expected to soon release the results of pivotal clinical trials of an experimental therapy for lupus.
    stat · 7d ago
  • STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem
    Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.
    stat · 7d ago
  • STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
    Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, Zolgensma.
    stat · 13d ago
  • STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
    Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, Zolgensma.
    stat · 13d ago
  • STAT+: A possible comeback for a failed sickle cell gene therapy
    Three years ago, a trial for a sickle cell gene-editing therapy a decade in the making ended abruptly after the first patient suffered a serious adverse event. Now, the therapy…
    stat · 13d ago
  • STAT+: Beyond statins, one drug lowered heart attack risk by 20%
    A new study could help doctors figure out what medicine to prescribe for cholesterol when statins don't cut it: It's “answering a really challenging clinical question."
    stat · 14d ago
  • STAT+: Medicare delays controversial remote patient monitoring rule to 2029
    Despite widespread opposition, Medicare will finalize a controversial proposal that will prevent providers, such as hospitals, from using third parties to deliver remote patient monitoring services.
    stat · 14d ago
  • STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
    Rasonque, Revolution Medicines' new pancreatic cancer drug, is off to one of the best oncology drug launches in history.
    stat · 14d ago
view all news mentions →
identifiers
ticker
$PMN
SEC CIK
0001374339
country
CA
source
sec_tickers
top tags
Alzheimer's Disease1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 18m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?